REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) Reviva Pharmaceuticals Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company’s lead product candidate comprises brilaroxazine (RP5063) for the treatment of neuropsychiatric indications, such as schizophrenia, bipolar disorder, major depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer’s disease, and Parkinson’s disease psychosis. It also engages in the clinical development for respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis. In addition, the company is in preclinical development for the treatment of psoriasis; and RP1208 for the treatment of depression and obesity. The company was founded in 2018 and is headquartered in Cupertino, California.
Sector: Pharmaceutical Preparations
Industry: Biotechnology
Reviva Pharmaceuticals Holdings, Inc. OTC:RVPH Healthcare · Biotechnology
All Press Release SEC Filings News
Press Release ⚠ 1
Reviva to Participate in the Lytham Partners Fall 2026 Investor Conference
Reviva Pharmaceuticals (OTCQB: RVPH) will present at the Lytham Partners Fall 2026 Investor Conference, with management's webcast scheduled for 12:30 PM ET on Tuesday, September 29, 2026, and a replay available afterward.
Founder, President and CEO Laxminarayan Bhat will lead the presentation, and management will also participate in virtual one-on-one meetings with investors throughout the event.
No new clinical, financial, or regulatory information was disclosed; the release is a routine investor-access item, with the pipeline still anchored on brilaroxazine (RP5063) and RP1208 and the planned RECOVER-2 Phase 3 trial evaluating brilaroxazine for schizophrenia.
• 1mo ago AI analysis › News
Financial Survey: InMed Pharmaceuticals (NASDAQ:INM) & Reviva Pharmaceuticals (NASDAQ:RVPH)
defenseworld.net • 2mo ago SEC Filing ● Critical ⚠ 6
RVPH: 10-Q · periodic report
Reviva Pharmaceuticals issued a going-concern warning in its Q2 2026 10-Q, disclosing that its $19.9 million of cash is not sufficient to satisfy operating cash needs for the 12 months from the filing date and that conditions raise substantial doubt about its ability to continue as a going concern. Management believes cash covers anticipated outlays into July 2027 but states additional fundraising is required, with no guarantees or commitments in place.
The quarter was defined by structural setbacks: the company completed a 1-for-20 reverse stock split on March 9, 2026, was delisted from Nasdaq after failing the $1.00 minimum bid price rule with trading suspended May 14, 2026, and now quotes on the OTCQB Venture Market under RVPH. Nasdaq filed a Form 25 on July 10, 2026 to formally strike the listing, and new risk factors flag reduced liquidity, penny stock status, and impaired capital-raising ability.
Management concluded the company did not maintain effective disclosure controls due to pervasive material weaknesses in its control environment, IT general controls, and process-level controls, with remediation underway. On the P&L, the Q2 net loss narrowed to $2.4 million from $6.1 million a year ago as R&D spending fell after completion of the Phase 3 RECOVER-1 trial, while shares outstanding more than doubled to 13.1 million following a $10.0 million gross March 2026 offering at $1.50 per share and $2.5 million of ATM sales.
SEC 10-Q • 2mo ago AI analysis › Press Release ⚠ 1
Reviva Reports Second Quarter 2026 Financial Results and Recent Business Highlights
Reviva reported a Q2 2026 net loss of $2.4 million, or $0.19 per share, significantly narrowing from the $6.1 million loss in the prior year as operating expenses decreased.
Cash position improved to $19.9 million as of June 30, 2026, up from $14.4 million at the end of 2025.
The company filed a new patent application for brilaroxazine targeting 2046 exclusivity and expects FDA feedback on the new formulation in Q4 2026, with RECOVER-2 Phase 3 enrollment planned for 1H 2027 pending additional financing.
• 2mo ago AI analysis › SEC Filing ● Critical ⚠ 3
RVPH: 25-NSE · delisting
The Nasdaq Stock Market has determined to remove the common stock of Reviva Pharmaceuticals Holdings, Inc. from listing effective at the opening of the trading session on July 20, 2026.
This action follows the company's failure to qualify for listing pursuant to Listing Rule 5550(a)(2) and its inability to meet the terms of a Decision Modification and Extension Letter after previously appealing the staff determination.
The company's stock was suspended from trading on May 14, 2026, and the staff's determination to delist became final on June 26, 2026.
SEC 25-NSE • 3mo ago Press Release
Life Sciences Virtual Investor Forum Presentations Now Available for On-Demand Viewing
Aspire Biopharma Holdings was listed as a presenting company at the recent Life Sciences Virtual Investor Forum hosted by Virtual Investor Conferences.
The company's presentation materials are now available for on-demand viewing and will remain accessible for 90 days.
This announcement was issued by the conference organizer, OTC Markets Group, and does not contain new material information about Aspire Biopharma.
• 4mo ago AI analysis › Press Release
Life Sciences Virtual Investor Forum Agenda Announced for June 24th & 25th
Aspire Biopharma Holdings (ASBP) is scheduled to present at the upcoming Life Sciences Virtual Investor Forum on June 25, 2026, at 2:00 PM ET.
The event is hosted by Virtual Investor Conferences and features a roster of life sciences companies, allowing investors to view presentations and schedule one-on-one meetings with management teams.
Registration is free and open to investors who wish to attend the live sessions or access recorded content.
• 4mo ago AI analysis › Press Release
Reviva Pharmaceuticals to Present at the Life Sciences Investor Forum on June 24th
Reviva Pharmaceuticals announced that CEO Laxminarayan Bhat will present at the Life Sciences Investor Forum on June 24, 2026.
Management is also available for one-on-one meetings on June 26 and June 30 to discuss the company's pipeline and strategy.
The company's current pipeline includes drug candidates brilaroxazine and RP1208 for CNS, inflammatory, and cardiometabolic diseases.
• 4mo ago AI analysis › Press Release
Reviva to Participate in Fireside Chat at A.G.P.’s Annual Healthcare Company Showcase
Reviva Pharmaceuticals CEO Laxminarayan Bhat will participate in a fireside chat at A.G.P.’s Annual Healthcare Company Showcase on May 20, 2026.
The session is scheduled for 2:40-3:00 PM ET and will feature equity research analyst Jim Molloy.
This is a standard investor relations appearance with no new clinical or financial disclosures attached.
• 5mo ago AI analysis › Press Release ⚠ 2
Reviva Reports First Quarter 2026 Financial Results and Recent Business Highlights
Reviva Pharmaceuticals reported a net loss of $3.2 million, or $0.46 per share, for the first quarter of 2026, compared to a net loss of $6.4 million, or $2.61 per share, in the same period last year.
The company's cash and cash equivalents increased to $22.2 million as of March 31, 2026, from $14.4 million as of December 31, 2025.
Reviva has filed a provisional patent application for a new form of brilaroxazine, aiming to extend patent life and commercial exclusivity through 2046. The company expects FDA feedback on this strategy in mid-2026.
Reviva's common stock will transition from Nasdaq to OTCQB Venture Market quotation on May 14, 2026, with the ticker symbol remaining 'RVPH'.
• 5mo ago AI analysis › SEC Filing ● Critical ⚠ 4
RVPH: 8-K · delisting
Reviva Pharmaceuticals Holdings, Inc. received notice from the Nasdaq Hearings Panel that its common stock will be delisted from The Nasdaq Capital Market due to non-compliance with the minimum bid price requirement of $1.00 per share. Trading on Nasdaq will be suspended as of the open of business on May 14, 2026.
Following the delisting, the Company's shares will begin trading on the OTCQB Venture Market under the existing symbol "RVPH." The Company warned that moving to the OTC market may materially reduce liquidity, market price, and its ability to raise equity financing.
SEC 8-K • 5mo ago AI analysis › Press Release
Reviva to Participate in a Fireside Chat Hosted by A.G.P. on Brilaroxazine’s Potential Across Multiple Neuropsychiatric Indications
Reviva Pharmaceuticals announced that CEO Dr. Laxminarayan Bhat will participate in a fireside chat hosted by A.G.P. Equity Research on April 27, 2026.
The discussion will focus on the clinical-stage candidate brilaroxazine, highlighting positive topline data from the Phase 3 RECOVER trial in schizophrenia and upcoming regulatory and IP milestones.
The company also plans to outline the expansion of brilaroxazine into other neuropsychiatric indications including bipolar disorder, MDD, and ADHD, as well as inflammatory diseases like PAH and IPF.
• 6mo ago AI analysis › News
Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) Receives Consensus Rating of “Moderate Buy” from Analysts
defenseworld.net • 6mo ago Press Release ● Major
Reviva Reports Full Year 2025 Financial Results and Recent Business Highlights
globenewswire.com • 6mo ago 
